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Background: To compare the effectiveness and complications of radiofrequency ablation (RFA) using cluster electrodes or internally cooled wet (ICW)
electrodes in patients with medium-sized hepatocellular carcinomas (HCCs).
Methods: Between February 2008 and September 2013, 40 patients (31 men and 9 women; mean age, 61.2 years) with a single medium-sized HCC (mean
size, 3.5  0.5 cm; range, 3.1–5.0 cm) underwent percutaneous RFA with cluster electrodes (n ¼ 19) or ICW electrodes (n ¼ 21). Technical success,
technical effectiveness, ablation volume, major complications, and local tumor progression were compared.
Results: After the initial RFA, technical success was achieved in 84% of patients and 90% of patients treated by cluster electrodes and ICW electrodes,
respectively (P ¼ 0.654). At 1 month, technical effectiveness was achieved by cluster electrodes and ICW electrodes in 84% and 100% of patients,
respectively (P ¼ 0.098). During follow-up period (mean, 17.8 months; range, 0–67 months), the median local tumor progression rates were 21.3 months
in the cluster group and 31.0 months in the ICW group. The 6-month, 1-, 2-, and 4-year local tumor progression rates were signiﬁcantly lower after RFA
with ICW electrodes (0%, 7%, 25%, and 57%, respectively) than after RFA with cluster electrodes (26%, 33%, 53%, and 68%, respectively; P ¼ 0.036). Major
complications occurred in 15.8% of patients treated with cluster electrodes and in 4.8% of patients treated with ICW electrodes (P ¼ 0.331).
Conclusion: For the treatment of medium-sized HCCs, percutaneous RFA using ICW electrodes results in lower rate of local tumor progression and fewer
serious complications, compared to cluster electrodes.
Copyright  2014, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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Percutaneous radiofrequency ablation (RFA) is a safe and effec-
tive treatment for local tumor control in patients with small
(3 cm) or medium-sized (3.1–5.0 cm) hepatocellular carcinomas
(HCCs).1–5 However, local tumor progression, a common signiﬁcant
prognostic factor of RFA-treated HCC,6 can be as high as 17–35%
after mean follow-up periods of 16–25.7 months.7–9 Furthermore,
local tumor progression is more common in patients with large
tumors.10,11 For medium-sized HCCs, the complete ablation
rates ranged from 53% to 74% according to previous studies on
RFA.11–13
Thus, a sufﬁciently large ablation zone is necessary to achieve
complete tumor destruction and lower local tumor recurrence
rates, especially in patients withmedium-sized HCC. To address the
many challenges of enlarged ablation zones, several types of elec-
trodes such as internally cooled needles,14 perfused needles,15 and
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treat HCCs >3 cm in diameter, multiple overlapping ablations are
often required to cover the entire tumor volume and the peripheral
ablation margins.16,17 However, this procedure is time consuming
and technically challenging because gas bubbles that form disturb
repositioning the electrode under ultrasound guidance, and
thereby leads to incomplete ablation.
To avoid problems related to multiple overlapping ablations
such as technical difﬁculties and a long procedural time, a cluster
electrode is typically used to treat medium-sized HCCs.18 A cluster
electrode may nevertheless demonstrate a higher incidence of
complications because of the greater difﬁculty of delicately
manipulating the cluster electrode to avoid damaging structures
such as the hepatic vessels. In addition, the consistently larger
ablation zone of a cluster electrode may contribute to collateral
thermal injury in adjacent organs.19
Internally cooled wet (ICW) electrodes combine the advantages
of cooled and saline-perfused electrodes.20 The ICW electrodeMedicine, Asan Medical Center, Seoul, Korea
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electrode cooling.20 The original ICW electrode had two coaxial
lumina, which thereby enabled the circulation of cooling water and
interstitial infusion of saline through side holes. A modiﬁed ICW
electrode was recently introduced with a simpler design that
consists of only one lumen and two microholes on the active tip.21–
23 However, no comparative studies had assessed the differences
between cluster and ICW electrodes in local therapeutic efﬁcacy
and safety. Therefore, we compared the effectiveness and compli-
cations of RFA using cluster and modiﬁed ICW electrodes for
treating patients with medium-sized HCCs.
Method
Patient population
Our Institutional Review Board (Asan Medical Center, Korea)
approved this retrospective review. Patients were included if they
had a single HCC measuring 3.1–5.0 cm in diameter, no imaging
evidence of vascular invasion, and no evidence of extrahepatic
disease. Patients were excluded if they had multiple HCCs, vascular
invasion, extrahepatic metastases, or coagulopathy (platelet count
<50  103/mL; international normalized ratio >1.5). Forty patients
treated between February 2008 and September 2013 met the in-
clusion criteria. The criteria for the diagnosis of HCC were based on
the guidelines of the American Association for the Study of Liver
Diseases.24 Nineteen patients underwent RFA with a cluster elec-
trode and 21 patients underwent RFA with an ICW electrode. The
radiologist who performed RFA chose the electrode based on
preference or availability. (This study used three radiologists.)
RFA system
All RFA procedures were percutaneously performed under ul-
trasound guidance with the patient under conscious sedation
(using midazolam hydrochloride) and local anesthesia (using
lidocaine hydrochloride). During the procedure, vital signs and
cardiac status were monitored by pulse oximetry and electrocar-
diography.We used an internally cooled electrode system during all
procedures. Two types of electrodes were used with a 200-W
radiofrequency generator: (1) a single 17-gauge straight ICW elec-
trode (RF Medical, Seoul, Korea) with a 3-cm active tip used to treat
21 patients and (2) a cluster type electrode (ValleyLab, Burlington,
MA, USA) with a 2.5-cm active tip used to treat 19 patients. The
internal structure of the exposed tip of the ICW electrode and the
conventional internally cooled electrode are identical, except the
ICW electrode contains two 0.03-mm side holes. When using ICW
electrodes with exposed 3-cm tips, 99% of chilled 0.9% isotonic
saline was administered at a rate of 1 mL/min for cooling and 1%
isotonic saline was infused at a rate of 1.2 mL/min.
All electrodes were placed via the transhepatic approach. The
radiofrequency current was emitted for 12 minutes using a 200-W
generator that was set to deliver maximum power using the
automatic impedance control method. The overlapping ablation
technique was used to treat 13 patients (average, 2.7 times; range,
2–4 times) in the ICW group and treat 10 patients (average, 2.9
times; range, 2–4 times) in the cluster group. Ablation time was
subject to the operators’ discretion, and based on tumor size, extent
of echogenic clouds, and patient condition (e.g., vital signs, pain).
The endpoint of ablationwas complete ablation of the visible tumor
and its margins, which were 0.5–1.0 cm into the normal liver pa-
renchyma surrounding the tumor. In some patients, artiﬁcial ascites
or pleural effusion was created to visualize the lesion or avoid
thermal injury to the adjacent diaphragm. After ablation, we
cauterized the electrode path during retraction of the electrode tominimize bleeding and tract seeding. Patients were discharged
from the hospital the day after the procedure if immediate post-
procedure computed tomography (CT) images or overnight clinical
observation showed no complications.
Follow-up
Contrast-enhanced CT examinations were performed <2 hours
or 1 day after RFA to evaluate the extent of the treated areas and
assess possible complications such as bleeding and ﬂuid collection.
Unenhanced CT scans were initially obtained, followed by contrast-
enhanced CT scans (contrast medium injection rate: 3.0 mL/s). The
contrast-enhanced CT scans were obtained during the hepatic
arterial phase (using bolus-tracking methods or 36-second delays),
the portal venous phase (72-second delay), and the equilibrium
phase (3-minute delay). Additional RFA was performed if residual
nodular enhancement was observed near the ablated area. How-
ever, transarterial chemoembolization (TACE) was performed if a
residual enhanced lesion was difﬁcult to target using RFA. One
month after the procedure, RFA efﬁcacy was evaluated using
contrast-enhanced CT. The 1-month CT examination consisted of a
second CT study, and the imaging technique was identical to the
ﬁrst CT that was performed after RFA.
If the 1-month CT showed a completely ablated tumor and no
new tumors were noted at other liver sites, subsequent follow-up
contrast-enhanced CT scans were obtained every 2–3 months. All
new tumorsdwhether in the ablated lesion or at other liver
sitesdpresent during the follow-up period were treatedwith RFA if
the patient still met the criteria for such treatment; if not, the le-
sions were treated by TACE.
Evaluation of ablation volume
To assess the ablation volume, CT analysis was performed
immediately after RFA or 1 day after RFA. Volumetric data were
obtained from the portal phase images, and the margins of the
ablated area were manually drawn slice-by-slice from top to bot-
tom. We calculated the volume using the summation-of-area
method.
Deﬁnition and evaluation of data
Data were analyzed on an intention-to-treat basis. Technical
success was deﬁned as treatment completion, based on the pro-
tocol, with complete coverage and adequate safety margins evident
at the time of the procedure.25 One month after RFA, technical
effectiveness was deﬁned as the complete ablation of the tumor on
imaging. At 1 month after RFA, local tumor progressionwas deﬁned
as nodular or irregular enhancement at any follow-up assessment.
Major complications were deﬁned as any event that required
additional treatment such as increased level of care, hospital stay
beyond the observation status (including readmission after initial
discharge), or permanent adverse sequelae such as substantial
morbidity, disability, or death.25 Tumors were categorized as non-
subcapsular or subcapsular, and subcapsular tumors were deﬁned
as lesions with margins located <1 cm from the liver surface.26 The
rates of technical success, technical effectiveness, ablation volume,
major complications, and local tumor progression were compared
between the two groups.
Statistical analysis
The Mann–Whitney U test was used to compare pairs of inde-
pendent continuous variables. Fisher’s exact test was used to
compare categorical variables. Local tumor progression rates were
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Gehan’s generalized Wilcoxon test (Breslow test). Patients who
underwent surgery or liver transplantation during the follow-up
period were censored. All statistical analyses were performed
using SPSS (version 21.0; SPSS Inc., Chicago, IL, USA). Two-sided
P < 0.05 were considered statistically signiﬁcant.
Results
Patient characteristics
Table 1 summarizes the characteristics of the patients in this
study. Of the 40 patients, 29 patients tested positive for hepatitis B
virus, six patients tested positive for hepatitis C virus, and ﬁve
patients tested negative for either virus. At the time of RFA, 39 of 40
patients had cirrhosis. The mean tumor size was 3.6  0.6 cm
(median size, 3.3 cm; range, 3.1–5.0 cm) in the cluster group and
3.4  0.3 cm (median size, 3.3 cm; range, 3.1–4.0 cm) in the ICW
group. There were no signiﬁcant between-group differences in
patient age, sex, positivity for hepatitis B or C virus, increase in
serum alpha-fetoprotein, Child-Pugh score, median tumor size, or
tumor location (i.e., subcapsular or nonsubcapsular).
Technical success and effectiveness
During the initial treatment, the 19 patients in the cluster group
underwent 20 ablations and the 21 patients in the ICW group un-
derwent 23 ablations. To visualize the lesion and avoid thermal
injury to the adjacent diaphragm, artiﬁcial ascites or pleural effu-
sion was required in four cluster group patients and in four ICW
group patients. Technical success after the ﬁrst RFA session was
achieved in 16 (84%) of 19 patients in the cluster group and in 19
(90%) of 21 patients in the ICW group (P ¼ 0.654; Fig. 1, 2) One of
three patients in the cluster group who had initial technical failure
received additional RFA for a residual enhanced lesion. One patient
in the cluster group underwent TACE because of a residual
enhanced lesion that was difﬁcult for RFA targeting. One patient in
the cluster group had technical failure because of developing car-
diac tamponade during the procedure. Two patients with initial
technical failure in the ICWgroup underwent additional RFA: one of
these patients had a residual enhanced lesion and the secondTable 1 Baseline Patient Characteristics
Demographics Cluster group ICW group P
Patients (n) 19 21
Age (y, mean  SD) 60.0  8.7 62.2  11.3 0.436
Sex 0.133
Male 17 14
Female 2 7
Etiology 0.543
HBV 15 14
HCV 2 4
Alcoholic 1 0
Unknown 1 3
Child-Pugh score 0.056
A 10 17
B 9 4
Serum AFP 0.577
<100 ng/mL 12 15
100 ng/mL 7 6
Tumor size (cm, mean  SD) 3.6  0.6 3.4  0.3 >0.999
Tumor location, no. of tumors 0.712
Subcapsular 14 17
Nonsubcapsular 5 4
AFP, a-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; ICW, internal
cooled wet; SD, standard deviation.patient had an insufﬁcient ablation margin after the initial RFA. The
interval between the ﬁrst and second RFA was within 1 day.
At the 1-month follow-up CT scan, 16 tumors in the cluster
group and 21 tumors in the ICW group were completely ablated,
which demonstrated technical effectiveness rates of 84% (16 of 19
patients) and 100% (21 of 21 patients; P ¼ 0.098), respectively.
Nodular enhancement near the ablated area was observed in two
patients in the cluster group. All lesions were successfully treated
using an additional RFA session (n ¼ 1) or TACE (n ¼ 1).
Ablation volume
The mean ablation volume was not statistically signiﬁcant,
although it tended to be larger in the ICW group (46.0  21.8 cm3;
range, 18.5–107.5 cm3) than in the cluster group (40.7  21.4 cm3;
range, 17.8–91.2 cm3; P ¼ 0.335).
Major complications
Major complications developed in three (15.8%) of 19 patients in
the cluster group and in one (4.8%) of 21 patients in the ICW group
(P ¼ 0.331). In the cluster group, one of the three patients devel-
oped hepatic parenchymal bleeding in the ablated area and
required conservative treatment, and one patient developed he-
patic surface bleeding and iatrogenic arterioportal shunting. The
latter patient was successfully treated by transarterial emboliza-
tion. Twelve minutes after initiating RFA to treat a segment II tumor
(i.e., subcapsular area) of the liver, one patient developed sudden
hemodynamic collapse. Cardiac tamponade was diagnosed on ul-
trasonography. Despite aggressive resuscitation, including evacua-
tion of the hemopericardium, the patient did not recover and
subsequently underwent exploratory thoracotomy. Injury to the
right coronary artery and signiﬁcant hemopericardium were
conﬁrmed during thoracotomy.
The patient died 1 day later. In two of the three patients with
bleeding complications in the cluster group, the tumors were
located in the subcapsular portion. In the ICW group, pleural effu-
sion requiring chest tube insertion or prolonged hospital stay
developed in one patient.
Local tumor progression rate
During the follow-up period (mean period, 17.8  17.3 months;
range, 0–67months), local tumor progression in the treated lesions
occurred in 8 (42.1%) of 19 patients in the cluster group and in 6
(28.6%) of 21 patients in the ICW group. The median local tumor
progression rates were 21.3  11.3 months in the cluster type group
and 31.0  2.7 months in the ICW group. Cumulative local tumor
progression rates at 6 months, 1-, 2-, and 4-years were 26%, 33%,
53%, and 68%, respectively, in the cluster group, and 0%, 7%, 25%,
and 57%, respectively, in the ICWgroup. The rates were signiﬁcantly
lower in the ICW group (P ¼ 0.036; Fig. 3).
Discussion
Sufﬁcient safety margins around the ablated areas sur-
rounding target tumors can decrease local tumor progression.27
However, RFA on medium-sized HCCs remains an important
therapeutic challenge because of the difﬁculty of creating sufﬁ-
cient safety margins.10,28,29 The methods used to increase abla-
tion volume include applying multiple overlapping treatments
in a contiguous fashion17 and using expandable electrodes.19,30
Multiple overlapping ablations are technically challenging and
placement errors are likely to occur because the electrode re-
quires multiple positions. This technical difﬁculty may be
Fig. 1. Computer tomography (CT) images of a 67-year-old man who underwent radiofrequency ablation (RFA) for a medium-sized hepatocellular carcinoma (HCC) using a cluster
electrode with a 2.5-cm active tip. (A) The arterial phase axial CT image 2 days prior to RFA shows a 3.3-cm diameter HCC in hepatic segment VIII (arrow). (B) The portal venous
phase axial CT image and (C) coronal CT image 1 hour after RFA show the ablation zone (arrows). The calculated volume of the ablation zone is 40.2 cm3.
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or tumors adjacent to major hepatic vessels.3 Large ablation
volumes have been achieved using cluster electrodes11,18; how-
ever, this may result in a higher incidence of complications
because of the greater difﬁculty in delicately manipulating
cluster electrodes to avoid damaging structures such as the he-
patic vessels.11
Kim et al22,23 recently reported that percutaneous RFA using
ICW electrodes is safe and provides successful local HCC tumor
control. The authors suggest that using the ICW electrode results in
consistent and large ablation volumes because it successfully
combines cooling and perfusion. The two microholes maintain a
controlled, reduced rate of saline infusion (1–1.2 mL/min) despite
the fast circulation rate (110 mL/min) delivered by the peristaltic
pump. Furthermore, these authors compared ablation volumes
between conventional internally cooled electrodes and ICW elec-
trodes. The ablation volumes, which were conﬁrmed using CT
immediately after RFA or 1 day after RFA, were signiﬁcantly larger
in the ICW group than in the conventional internally cooled group
using 2 cm exposed tips [14.5 cm3 (ICW group) vs. 6.2 cm3 (con-
ventional group); P < 0.001] and 3 cm exposed tips [32.7 cm3 (ICW
group) vs. 15.2 cm3 (conventional group); P < 0.001]. These results
are similar to results obtained in ex vivo bovine and in vivo porcine
livers.21
To our knowledge, this is the ﬁrst study to compare the safety
and efﬁcacy of RFA using cluster and ICW electrodes in patientsFig. 2. Computed tomography (CT) images of a 49-year-old womanwho underwent radiofreq
electrode with a 3-cm active tip. (A) The arterial phase axial CT image 7 days prior to RFA s
venous phase axial CT image and (C) coronal CT image 1.5 hours after RFA show the ablatiwith medium-sized HCCs. The ICW electrodes, compared to the
cluster electrodes, tended to yield higher initial technical success
(90% vs. 84%, respectively) and technical effectiveness rates (100%
vs. 84%, respectively). During a mean follow-up period of 17.8
months (range, 0–67months), the local tumor progression rate was
signiﬁcantly lower in ICW-treated patients than cluster electrode-
treated patients (26%, 33%, 53%, and 68% in the cluster group vs.
0%, 7%, 25%, and 57% in the ICW group at 6 months, 1-, 2-, and 4-
years, respectively; P ¼ 0.036). These ﬁndings indicate that RFA
using ICW electrodes provides better local tumor control and re-
sults in lower rates of local tumor progression, compared to cluster
electrodes, for treating medium-sized HCCs.
The major complication rate was higher using cluster electrodes
(15.8%) in comparison to ICWelectrodes (4.8%; P¼ 0.331), although
this difference was not statistically signiﬁcant. To avoid incomplete
ablation, the tip of the cluster electrodewould have to extend to the
end of the tumor. When tumors are located in the subcapsular area
or close to other organs such as the diaphragm, gallbladder, and
gastrointestinal tract, extension of the cluster electrode may in-
crease the likelihood of injury to the liver capsule or adjacent or-
gans. In our study, 31 of 40 HCCs were located in the subcapsular
portion. Two of three patients who developed hemorrhagic com-
plications after RFA using cluster electrodes also had subcapsular
HCCs.
Furthermore, hemorrhagic cardiac tamponade resulted in the
death of one patient after RFA in which the cluster electrode wasuency ablation (RFA) for a medium-sized hepatocellular carcinoma (HCC) using an ICW
hows a 3.3-cm diameter HCC between hepatic segments V–VIII (arrow). (B) The portal
on zone (arrows). The calculated volume of the ablation zone is 57.0 cm3.
Fig. 3. The Kaplan–Meier curves show the rates of local tumor progression in the cluster electrode group and ICW electrode group. ICW, internally cooled wet.
Gastrointestinal Intervention 2014 3(2), 98–103102to treat a lesion in hepatic segment II. Several articles report
potentially fatal complications during RFA using expandable
electrode needles. In 2005, Moumouth et al31 reported the ﬁrst
case of cardiac tamponade during RFA of a lesion in hepatic
segment II. These authors proposed two possible explanations for
the cardiac tamponade. First, it may be difﬁcult to ascertain the
exact location of the expandable RFA electrodes and ensure that
none of the expandable electrodes are in the diaphragm or peri-
cardium, although the position of the electrodes was checked
prior to starting the procedure. Second, the in vivo distribution of
heat may be unpredictable, and the pericardium may be thermally
damaged by heat conduction, which has been demonstrated in
other visceral organs.32 Silverman et al33 recently presented two
cases of hepatocellular carcinoma in segment II of the liver in
which the tumors were a major risk factor for cardiac tamponade
during RFA.
By contrast, the ICW electrode may not have to be close to the
liver capsule or adjacent organs, and thereby reduce the potential
risks of unintended injury. In addition, the ICW needle, which can
be more conﬁdently positioned and monitored, may be a good
alternative and prevent fatal complications such as cardiac tam-
ponade during ablation of a subcapsular lesion in segment II of the
liver.
The principal limitation of this study is its retrospective and
nonrandomized design and the use of electrodes in patients with
medium-sized HCCs was individually determined based on the
attending physician’s preference or electrode availability. This
likely led to selection bias in our study population. In addition, the
number of patients enrolled in our study was relatively small.
Therefore, a prospective, large-series, randomized, controlled trial
is required that compares the clinical efﬁcacy and complication rate
of cluster and ICW electrodes for clinically treating medium-sized
HCCs. In conclusion, percutaneous RFA using ICW electrodes re-
sults in lower rates of local tumor progression and less serious
complications, compared to RFA using cluster electrodes, for the
treatment of medium-sized HCCs.Conﬂicts of interest
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